Show simple item record

dc.contributor.authorGill, Sonja Jen
dc.contributor.authorTravers, Jonen
dc.contributor.authorPshenichnaya, Irinaen
dc.contributor.authorKogera, Fiona Aen
dc.contributor.authorBarthorpe, Syden
dc.contributor.authorMironenko, Tatianaen
dc.contributor.authorRichardson, Lauraen
dc.contributor.authorBenes, Cyril Hen
dc.contributor.authorStratton, Michael Ren
dc.contributor.authorMcDermott, Ultanen
dc.contributor.authorJackson, Stephenen
dc.contributor.authorGarnett, Matthew Jen
dc.identifier.citationPLoS ONE 2015, 10(10): e0140988. doi:10.1371/journal.pone.0140988en
dc.description.abstractEwing’s sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing’s sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition and this is being evaluated in clinical trials, although the mechanism of hypersensitivity has not been directly addressed. PARP inhibitors have efficacy in tumors with BRCA1/2 mutations, which confer deficiency in DNA double-strand break (DSB) repair by homologous recombination (HR). This drives dependence on PARP1/2 due to their function in DNA single-strand break (SSB) repair. PARP inhibitors are also cytotoxic through inhibiting PARP1/2 auto-PARylation, blocking PARP1/2 release from substrate DNA. Here, we show that PARP inhibitor sensitivity in Ewing’s sarcoma cells is not through an apparent defect in DNA repair by HR, but through hypersensitivity to trapped PARP1-DNA complexes. This drives accumulation of DNA damage during replication, ultimately leading to apoptosis. We also show that the activity of PARP inhibitors is potentiated by temozolomide in Ewing’s sarcoma cells and is associated with enhanced trapping of PARP1-DNA complexes. Furthermore, through mining of large-scale drug sensitivity datasets, we identify a subset of glioma, neuroblastoma and melanoma cell lines as hypersensitive to the combination of temozolomide and PARP inhibition, potentially identifying new avenues for therapeutic intervention. These data provide insights into the anti-cancer activity of PARP inhibitors with implications for the design of treatment for Ewing’s sarcoma patients with PARP inhibitors.
dc.description.sponsorshipResearch in the M.J.G. laboratory is supported by grants from the Wellcome Trust (086357 and 102696/Z/13/Z; Research in the S.P.J. laboratory is funded by Cancer Research UK Program Grant C6/A11224 (, the European Research Council ( the European Community Seventh Framework Program grant agreement no. HEALTH-F2-2010-259893 (DDResponse). Core infrastructure funding was provided by Cancer Research UK Grant C6946/A14492 and Wellcome Trust Grant WT092096. S.P.J. receives a salary from the University of Cambridge, supplemented by Cancer Research UK. J.T. was funded by the European Community Seventh Framework Program grant agreement no. HEALTH-F2-2010-259893 (DDResponse). U.M. is supported by a Cancer Research UK Clinician Scientist Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.rightsAttribution 2.0 UK: England & Wales*
dc.titleCombinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcomaen
dc.description.versionThis is the final version of the article. It first appeared from PLOS via
prism.publicationNamePLOS ONEen
dc.rioxxterms.funderWellcome Trust
dc.contributor.orcidJackson, Stephen [0000-0001-9317-7937]
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idCancer Research UK (11224)
pubs.funder-project-idWellcome Trust (092096/Z/10/Z)
pubs.funder-project-idCancer Research UK (A14492)

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 2.0 UK: England & Wales
Except where otherwise noted, this item's licence is described as Attribution 2.0 UK: England & Wales